In the BioHarmony Drug Report Database

"Preview" Icon

Tirbanibulin

Klisyri (tirbanibulin) is a small molecule pharmaceutical. Tirbanibulin was first approved as Klisyri on 2020-12-14. It has been approved in Europe to treat actinic keratosis. It is known to target proto-oncogene tyrosine-protein kinase Src. Klisyri’s patents are valid until 2038-09-07 (FDA).

 

Trade Name

 

Klisyri
 

Common Name

 

tirbanibulin
 

ChEMBL ID

 

CHEMBL571546
 

Indication

 

actinic keratosis
 

Drug Class

 

Antineoplastics (mitotic inhibitors,tubulin binders

Image (chem structure or protein)

Tirbanibulin structure rendering